Project Grant R43CA295403
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $400,000 in funding to Electronic Biosciences, Inc. to develop a novel nanopore-based sequencing approach capable of accurately characterizing repetitive DNA sequences. The project aims to address limitations of current sequencing-by-synthesis methods in accurately sequencing genomic repeats, which are known to harbor variations associated...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $881,647 Project Grant to Panome Bio Inc. under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The grant supports research to advance untargeted metabolomics approaches for biomarker discovery in colon cancer. Specifically, Panome Bio is developing novel software and analytical methods to enhance the value and impact of untargeted metabolomics by addressing...
- The National Cancer Institute (NCI) awarded a $902,046 Project Grant under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program to Data Driven Bioscience Inc. on January 1, 2025. The grant supports the clinical validation of DuoSeq, a next-generation sequencing (NGS) platform that provides simultaneous DNA and RNA sequencing for the diagnosis of blood cancers. DuoSeq aims to overcome key limitations of existing NGS approaches by streamlining sample preparation,...
- The National Cancer Institute (NCI) awarded a $2,855,619 Project Grant titled "Empowering Cancer Detection and Monitoring with CAMPEX - CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles" to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), aims to advance CAMPEX, an integrated platform for highly sensitive and precise analysis of...
- The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...
- The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $404,994 Project Grant to Aperture Bio, Inc., a woman-owned small business in Cambridge, Massachusetts. The grant, awarded on March 1, 2025, supports the development and assessment of Aperture Bio's cyclic immunofluorescent imaging platform for pre-clinical applications in drug development, cell therapy manufacturing, regenerative medicine, and oncology research. The goal of the project is...
- The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $384,418 Project Grant to Xgenomes Corp. on September 25, 2024 to develop a revolutionary DNA sequencing platform. The project aims to create a super-resolution single-molecule sequencing technology that can read short sequence "words" rather than individual nucleotides, enabling one or more orders of magnitude improvements in accuracy and cost over...
- The University of Washington was awarded a $369,468 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct research on efficient, cost-effective, and ultrasensitive sequencing of somatic mutations and methylation. This 3-year grant, running from September 1, 2025 to August 31, 2028, will support the development of innovative next-generation sequencing (NGS) technologies to enable the identification of prognostic and therapeutically...
- The National Cancer Institute awarded a $1,320,861 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to GE Medical Systems Information Technologies, Inc. (doing business as GE Healthcare Technology & Innovation Center) to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. The objective is to democratize biobanking for low-resource institutes by leveraging tumor touch imprints on...